1.Values of fibrinogen degradation products (FDPs) and D-dimmer in healthy people
Journal of Practical Medicine 2002;435(11):42-43
The study involved 32 healthy blood donors (16 men and 6 women). Plasma D-dimer and FDPs levels were determined by semi-quantitative method, using chemical procedure of the Stago Inc., France. The results showed that plasma FDPs level in healthy people was lower than 40 g/ml (93.75% of the participants had lees than 20 g/ml). Plasma D-dimer level was 1-4 g/ml, with 75% of the participants had D-dimer values ranged from 1 to 2 g/ml.
Fibrin Fibrinogen Degradation Products
;
Pharmaceutical Preparations
2.D-dimer as a Prognostic Tool in Patients with Normotensive Pulmonary Embolism.
Jae Chol YOON ; Won Young KIM ; Sang Sik CHOI ; Sang Ku JUNG ; Chang Hwan SOHN ; Won KIM ; Kyoung Soo LIM ; Tae O JEONG ; Young Ho JIN ; Jae Baek LEE
Tuberculosis and Respiratory Diseases 2010;68(2):87-92
BACKGROUND: D-dimer testing is widely applied as a first step in the diagnostic work-up of pulmonary embolism (PE). Although this is the most sensitive assay for ruling out PE, the prognostic implications of D-dimer testing in patients with normotensive PE are not well known. The aim of this study was to determine if D-dimer testing on admission predicts major adverse cardiac events (MACE) in patients with normotensive PE. METHODS: A total of 180 consecutive patients with normotensive PE admitted between January 2003 and June 2009 were included. The group was divided into quartiles on the basis of their D-dimer levels. We compared the frequency of MACE by quartile of D-dimer level and estimated sensitivity, specificity, and predictive values for MACE in the first and fourth quartile. RESULTS: In the 37 (20.6%) patients with MACEs, the median D-dimer level (7.94 [IQR: 4.03~18.17] microgram/mL) was higher than in patients with a benign course (5.29 [IQR: 2.60~11.52] microgram/mL, p<0.01). The occurrence of MACEs was increased with increasing D-dimer level (p=0.017). In the first quartile (D-Dimer <2.76 microgram/mL) sensitivity, specificity, and positive and negative predictive values for predicting MACEs were, respectively, 91.9%, 29.4%, 25.2%, and 93.3%. CONCLUSION: Patients with D-dimer levels below 2.76 microgram/mL have a low risk of MACEs. Our study suggest that D-dimer level may be used to identify low risk patients with normotensive PE.
Fibrin Fibrinogen Degradation Products
;
Humans
;
Prognosis
;
Pulmonary Embolism
;
Resin Cements
3.The Change of Plasma Concentrations of Fibrinogen Degradation Products and Fibrin Degradation Products During the Open Heart Surgery.
Seong Cheal RYU ; Sung WOO ; Kang Hee CHO ; Yeong Gwon GOO ; Sung Sub PARK
Korean Journal of Anesthesiology 1993;26(3):499-505
There were many researches, which qualitative or quantitative assays were performed about fibrinolysis and the degree of activation of coagulation system. Authors measured fibrinogen degradation products(FbDP) and fibrin degradation products(FbDP) by monoclonal enzymeimmunoassay, instead of polyclonal method in 12 cases of cardiopulmonary bypass(CPB). 1) The increase of FgDP after sternotomy is verifying the significant fibrino(geno) lysis occured by stimulation of sternotomy. 2) By the result that FgDP was significantly increased compared with FbDP, primary fibrinogenolysis is more important phenomenon than secondary fibrinolysis during CPB. 3) FbDP and FgDP were most significantly increased immediately before the end of CPB and after CPB. 4) Increased FgDP was decreased after CPB but FbDP was still elevated 5 hours after CPB. According to the above results, CPB induced primary fibrinogenolysis and secondary fibrinolysis in open heart surgery.
Cardiopulmonary Bypass
;
Fibrin Fibrinogen Degradation Products*
;
Fibrin*
;
Fibrinogen*
;
Fibrinolysis
;
Heart*
;
Plasma*
;
Sternotomy
;
Thoracic Surgery*
4.D-Dimer Testing in Laboratory Practice.
Laboratory Medicine Online 2012;2(3):119-125
BACKGROUND: D-dimer is a reliable and sensitive index of fibrin deposition and stabilization. As such, its presence in plasma should be indicative of thrombus formation. There are many conditions unrelated to thrombosis in which D-dimer concentrations are high, however, making its positive predictive value rather poor. CONTENT: Notwithstanding these limitations, D-dimer can be regarded as a most valuable laboratory tool to diagnose and manage a vast array of thrombosis related clinical conditions, including (a) diagnosis of venous thromboembolism (VTE), (b) identification of individuals at increased risk of first thrombotic event (both arterial and venous), (c) identification of individuals at increased risk of recurrent VTE, (d) establishment of the optimal duration of secondary prophylaxis after a first episode of VTE, (e) pregnancy monitoring, and (f) diagnosis/monitoring of disseminated intravascular coagulation (DIC). This article is aimed at reviewing the merits and pitfalls of these applications. SUMMARY: From my analysis of the literature, I draw the following conclusions. (a) D-dimer, as measured by a sensitive test, can be safely used to exclude VTE in symptomatic outpatients, provided that it is used in combination with the pretest clinical probability. (b) High concentrations of D-dimer are associated with an increased risk of recurrent VTE. (c) Patients who present with D-dimer above cutoff after stopping the regular course of oral anticoagulation benefit from extended prophylaxis. (d) Finally, D-dimer can be used as a fibrin-related degradation marker for the diagnosis/management of patients with DIC.
Dacarbazine
;
Disseminated Intravascular Coagulation
;
Fibrin
;
Fibrin Fibrinogen Degradation Products
;
Humans
;
Outpatients
;
Plasma
;
Pregnancy
;
Thrombosis
;
Venous Thromboembolism
5.D-Dimer Testing in Laboratory Practice.
Laboratory Medicine Online 2012;2(3):119-125
BACKGROUND: D-dimer is a reliable and sensitive index of fibrin deposition and stabilization. As such, its presence in plasma should be indicative of thrombus formation. There are many conditions unrelated to thrombosis in which D-dimer concentrations are high, however, making its positive predictive value rather poor. CONTENT: Notwithstanding these limitations, D-dimer can be regarded as a most valuable laboratory tool to diagnose and manage a vast array of thrombosis related clinical conditions, including (a) diagnosis of venous thromboembolism (VTE), (b) identification of individuals at increased risk of first thrombotic event (both arterial and venous), (c) identification of individuals at increased risk of recurrent VTE, (d) establishment of the optimal duration of secondary prophylaxis after a first episode of VTE, (e) pregnancy monitoring, and (f) diagnosis/monitoring of disseminated intravascular coagulation (DIC). This article is aimed at reviewing the merits and pitfalls of these applications. SUMMARY: From my analysis of the literature, I draw the following conclusions. (a) D-dimer, as measured by a sensitive test, can be safely used to exclude VTE in symptomatic outpatients, provided that it is used in combination with the pretest clinical probability. (b) High concentrations of D-dimer are associated with an increased risk of recurrent VTE. (c) Patients who present with D-dimer above cutoff after stopping the regular course of oral anticoagulation benefit from extended prophylaxis. (d) Finally, D-dimer can be used as a fibrin-related degradation marker for the diagnosis/management of patients with DIC.
Dacarbazine
;
Disseminated Intravascular Coagulation
;
Fibrin
;
Fibrin Fibrinogen Degradation Products
;
Humans
;
Outpatients
;
Plasma
;
Pregnancy
;
Thrombosis
;
Venous Thromboembolism
6.Correlation between Serum D-Dimer Level and Volume in Acute Ischemic Stroke.
Young Woo PARK ; Eun Jeong KOH ; Ha Young CHOI
Journal of Korean Neurosurgical Society 2011;50(2):89-94
OBJECTIVE: D-dimer is a breakdown product of fibrin mesh after factor XIII stabilization. Previously, many authors have demonstrated a relationship between D-dimer level and stroke progression or type. This study aimed to investigate the relationship between D-dimer level and stroke volume. METHODS: Between January 2008 and December 2009, we analyzed the D-dimer levels of 59 acute ischemic stroke patients in our neurosurgical department both upon admission and after seven days of initial treatment. Each patient's National Institute of Health Stroke Scale score, modified Rankin Scales score, Glasgow outcome score, and infarction volume were also evaluated. RESULTS: Mean D-dimer level at admission was 626.6 microg/L (range, 77-4,752 microg/L) and the mean level measured after seven days of treatment was 238.3 microg/L (range, 50-924 microg/L). Mean D-dimer level at admission was 215.3 microg/L in patients with focal infarctions, 385.7 microg/L in patients with multiple embolic infarctions, 566.2 microg/L in those with 1-19 cc infarctions, 668.8 microg/L in 20-49 cc infarctions, 702.5 microg/L in 50-199 cc infarctions, and 844.0 microg/L in >200 cc infarctions (p=0.044). On the 7th day of treatment, the D-dimer levels had fallen to 201.0 microg/L, 293.2 microg/L, 272.0 microg/L, 232.8 microg/L, 336.6 microg/L, and 180.0 microg/L, respectively (p=0.530). CONCLUSION: Our study shows that D-dimer level has the positive correlation with infarction volume and can be use to predict infarction-volume.
Factor XIII
;
Fibrin
;
Fibrin Fibrinogen Degradation Products
;
Humans
;
Infarction
;
Stroke
;
Weights and Measures
7.Evaluation of an Automated Coagulation Analyzer Coapresta 2000.
Jonghyeon CHOI ; Sungwook SONG ; Yongjung PARK ; Jong Rak CHOI ; Jaewoo SONG
Laboratory Medicine Online 2011;1(2):94-99
BACKGROUND: The Coapresta 2000 (Sekisui Medical CO., LTD, Japan) is a fully automated random-access multiparameter hemostasis coagulation analyzer, which is equipped with a photo-optical clot detection unit and a cap-piercing system. It is able to perform clotting time assays as well as colorimetric assays (synthetic substrate method and latex turbidimetric method). In this study, we evaluated the analytical performance of the Coapresta 2000 for coagulation test items and compared with that of the ACL-TOP (Instrumentation Laboratory, Lexingtion, MA, USA) analyzer, which is currently used for routine coagulation test items in our hospital. METHODS: The Coapresta 2000 was evaluated with respect to its technical characteristics in the determination of 8 routine coagulation test items: prothrombin time, activated partial thromboplastin time, fibrinogen, fibrin-degradation product (FDP) antithrombin III, D-dimer, factors VIII and IX. Analyse-it (Analyse-it Software Ltd, UK) and SigmaStat (Systat Software, Inc., USA) were used for statistical analysis between items on the Coapresta 2000 and the ACL-TOP analyzer. RESULTS: The intra-assay and inter-assay coefficients of variation (CV) were below 5% for both groups of samples having values within the reference interval and outside the reference interval. Significant interference was observed with hemolytic and icteric samples. Carryover was not detected. The results obtained by Coapresta 2000 were well correlated with those obtained by the ACL-TOP analyzer (r2 in the range from 0.781 to 0.969). CONCLUSIONS: We concluded that Coapresta 2000 analyzer was well correlated with ACL-TOP analyzer for the routine coagulation test items tested.
Antithrombin III
;
Fibrin Fibrinogen Degradation Products
;
Fibrinogen
;
Hemostasis
;
Latex
;
Partial Thromboplastin Time
;
Prothrombin Time
8.Clinical and genetic analysis of 8 Chinese pedigrees with inherited dysfibrinogenemia.
Minghua JIANG ; Xiaoou WANG ; Kuangyi SHU ; Weiyan JIANG ; Ying HUANG ; Ying LIN ; Shanshan LI ; Yunliang HU
Chinese Journal of Medical Genetics 2014;31(2):134-139
OBJECTIVETo analyze clinical manifestation and genetic mutations in 8 Chinese pedigrees featuring hereditary dysfibrinogenemia.
METHODSProthrombin time(PT), activated partial thromboplastin time(APTT), thrombin time(TT), calibration of plasma protamine sulfate against TT, fibrinogen (Fg) activity, coagulation factors II, V, VII, VIII, IX, X, XI and XII of all probands and their family members were detected with an automatic blood coagulation analyzer; D-dimer(D-D) and fibrin(ogen) degradation products(FDPs) were also dtected by automatic blood coagulation analyzer, Fg antigen were detected with an immunoturbidimetry method. Exons of fibrinogen genes FGA, FGB and FGG and flanking sequences were amplified by polymerase chain reaction(PCR) and sequenced.
RESULTSAll of the probands showed normal levels of FDPs, D-dimer(D-D) and activity of coagulation factor II,V,VII, VIII, IX,X,XI, XII. Plasma PT and APTT were normal or slightly prolonged. Prolonged TT was found in all of the probands, whilst TT was not significantly shortened by protamine sulfate. Fg antigen was within the normal range, but Fg activity was significantly decreased. The Fg antigen/activity ratio was greater than 2. One proband has carried a heterozygous variant of the FGA gene g.1233G>A(p.A α Arg35His). Four have carried a heterozygous mutation of the FGB gene g.9692A>G(p.Bβ Asn190Ser). The remaining 3 had heterozygous substitution of FGG gene g.10819G>A(p.γ Arg301His). In addition, 2 polymorphisms (p.A α Thr331Ala) and p.B β Arg478Lys) were identified in FGA and FGB genes.
CONCLUSIONp.A α Arg35His, p.B β Asn190Ser and p. γ Arg301His are responsible for the inherited dysfibrinogenemia in the 8 Chinese pedigrees. p.B β Asn190Ser is firstly reported in China. p.B β Asn190Ser and p. γ Arg301His may be mutation hot spot in the Chinese population.
Afibrinogenemia ; blood ; genetics ; Fibrin Fibrinogen Degradation Products ; analysis ; Fibrinogen ; analysis ; genetics ; Humans ; Pedigree
9.Hypercoagulable state in patients with multiple myeloma.
Zeng-Yan LIU ; Guo-Qiang ZHANG ; Wen-Zheng YU ; Xue-Xia WANG ; Jian-Rong SUN ; Na GAO ; Hua LU
Journal of Experimental Hematology 2015;23(1):142-145
OBJECTIVEThis study was to detect the plasma thrombomodulin (TM), D-dimer and fibrinogen in patients with multiple myeloma (MM) and to analyze their relationship with morbid state, and also to investigate the relationship of the expression of coagulation factor with the ratio of myeloma cells.
METHODSELISA was used to detect the TM level in 45 cases of MM at different stages. The plasma level of D-dimer and fibrinogen was detected by STA automatic coagulation analyser.
RESULTSThe level of plasma TM in newly diagnosed patients was higer than that in normal control group and in platform stage group (P < 0.01; P < 0.05). There were significant differences between relapsed or refractory group and normal control group or those reached platform stage group (P < 0.05). Meanwhile, the level of plasma TM in the group of thalidomide combined with chemotherapy was higer than that in newly diagnosed patients (P < 0.05). The level of plasma D-dimer and fibrinogen of MM patients was higher than that in normal controls (P < 0.01;P < 0.05). The expression of D-Dimer in relapsed or refractory group reached the maximum. Also, the level of plasma D-Dimer in group of thalidomide combined chemotherapy was higer than in newly diagnosed patients (P < 0.05). The expression of coagulation factor did not correlate with the ratio of myeloma cells.
CONCLUSIONSLevel of plasma TM, D-Dimer and fibrinogen of MM patients is higher than that in control group. The level of plasma TM and D-Dimer can be elevated when thalidomide used, which indirectly suggested the tendency for thrombosis in MM patients.
Blood Coagulation Tests ; Fibrin Fibrinogen Degradation Products ; Fibrinogen ; Humans ; Multiple Myeloma ; Thalidomide ; Thrombomodulin ; Thrombosis
10.Levels of D-dimer, fibrinogen, and fibrinogen degradation product in patients with acute chest pain.
Fangjie ZHANG ; Xiangmin LI ; Juan ZHANG ; Aimin WANG ; Liping ZHOU ; Xiaogang LI
Journal of Central South University(Medical Sciences) 2019;44(11):1209-1213
To determine the relationship among the levels of D-dimer, fibrinogen (FIB), and fibrin degradation products (FDP) in acute fatal chest pain patients.
Methods: We retrospectively analyzed the patients with aortic dissection (AD), pulmonary embolism (PE) or acute myocardial infarction (AMI) from May 1, 2017 to April 30, 2018. All the patients had a chest and/or back pain. Levels of D-dimer, FIB, and FDP were examined at the time of admission, and the patients were further diagnosed by computed tomography angiography (CTA) or percutaneous transluminal coronary intervention (PCI). The levels and negative rates of D-dimer, FIB, and FDP in patients with AD, PE, and AMI were compared.
Results: A total of 234 patients were enrolled, including 95 AD, 98 AMI, and 41 PE. In the AD group, the AMI group and the PE group, the negative ratios of D-dimer were 13.68%, 70.41% and 4.88%, respectively; the negative ratios of FDP were 24.21%, 81.63% and 24.39%, respectively. There was no significant difference in negative rates of D-dimer and FDP between the AD group and the PE group (all P>0.05), but negative rates of D-dimer and FDP were significantly higher in the AMI group than those in the AD group and the PE group (all P<0.001). The level of D-dimer in the AMI group was significantly lower than that in the AD group or in the PE group (both P<0.001), while there was no statistically significant difference between the AD group and the PE group (P>0.05). However, there were no significant difference in the FIB levels among 3 groups (all P>0.05). The FDP level in the AMI group was significantly lower than that in the AD group or in the PE group (both P<0.001), while there was no statistically significant difference between the AD group and the PE group (P>0.05).
Conclusion: The levels of D-dimer and FDP are increased in AD and PE patients and may be as the useful biomarkers for the high-risk chest pain patients but not for AMI.
Chest Pain
;
Fibrin Fibrinogen Degradation Products
;
Fibrinogen
;
Humans
;
Percutaneous Coronary Intervention
;
Pulmonary Embolism
;
Retrospective Studies